Q-omics provides the consensus-scored KIAA1109 profile across patient tissues and cancer cell-line models. KIAA1109 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KIAA1109 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, KIAA1109 RNA expression shows 21,565 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where KIAA1109 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA1109 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA1109 survival associations across molecular data types. KIAA1109 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA1109 RNA expression–survival associations across cancer types. High KIAA1109 expression shows favorable associations in KIRC, READ, BRCA, SKCM, HNSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KIAA1109 RNA expression.
This table summarizes KIAA1109 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KIAA1109. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA1109 shows lower tumor expression in THCA, COAD, BRCA, KIRC, KIRP and LUSC. The THCA box plot shows higher KIAA1109 RNA expression in normal versus tumor tissue (log2 FC = −1.087, t-test p < 0.001).
This table shows molecular features associated with KIAA1109 in patient tissues and cancer cell lines. In patient samples, KIAA1109 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA1109 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
